Table 2.
Progression of spherical equivalent and axial length for children receiving atropine 0.5% as a starting dose.
| Continued therapy N = 89 (71.8%) | Ceased therapy N = 35 (28.2%) | |||||
|---|---|---|---|---|---|---|
| Increased dose N = 32 | Decreased dose N = 26 | Same dose N = 31 | Allergy stopb N = 9 | Adverse eventsc N = 17 | Lost to follow-up N = 9 | |
| Median age (year) myopia onset (IQR) | 6.0 (3) | 7.0 (4) | 6.0 (4) | 6.0 (5) | 6.0 (5) | 7.0 (6) |
| Median age (year) at baseline (IQR) | 8.5 (3) | 11.0 (4) | 9.0 (3) | 9.0 (4) | 11.0 (5) | 12.0 (6) |
| Median spherical equivalent (SE) in D | ||||||
| 1 year prior to treatment | −4.5 (4.9) | −2.9 (3.9) | −3.8 (3.1) | −3.6 (6.4) | −4.3 (4.5) | −4.8 (4.1) |
| Baseline | −5.8 (3.5) | −4.4 (2.8) | −4.9 (2.8) | −5.4 (4.9) | −5.3 (4.0) | −5.4 (3.0) |
| 1st year | −6.0 (3.6) | −4.2 (3.5) | −4.8 (2.5) | −7.5 (6.7) | −5.6 (3.7) | – |
| 2nd year | −6.9 (4.7) | −4.6 (2.8) | −5.2 (2.6) | −8.0 (5.5) | −6.8 (3.3) | – |
| 3rd year | −7.5 (5.2) | −4.8 (2.6) | −5.6 (2.6) | −8.1 (6.0) | −7.8 (3.7) | – |
| Median progression rate of SE in D/year | ||||||
| 1 year before treatment | −1.0 (1.3) | −1.3 (1.0) | −1.0 (1.2) | −1.1 (2.1) | −0.8 (1.1) | −0.4 (1.0) |
| 1st year | −0.4 (0.6) | +0.2 (0.7) | +0.1 (0.5) | −0.4 (0.7) | −0.7 (1.1) | – |
| 2nd year | −0.6 (0.7) | −0.3 (0.4) | −0.3 (0.6) | −0.9 (1.3) | −0.8 (0.9) | – |
| 3rd year | −0.5 (0.8) | −0.3 (0.3) | −0.3 (0.5) | −0.4 (1.4) | −0.9 (1.1) | – |
| Median axial length (AL) in mma | ||||||
| Baseline | 25.2 (1.3) | 24.7 (1.3) | 25.4 (1.6) | 25.2 (2.8) | 24.8 (1.2) | 25.9 (2.5) |
| 1st year | 25.5 (1.7) | 24.5 (1.5) | 25.3 (1.6) | 25.4 (1.5) | 25.1 (1.3) | – |
| 2nd year | 25.8 (1.4) | 24.7 (1.3) | 25.3 (1.6) | – | – | – |
| 3rd year | 25.9 (2.3) | 24.8 (1.5) | 25.4 (1.5) | – | – | – |
| Median progression rate AL in mm/yeara | ||||||
| 1st year | 0.3 (0.2) | 0.0 (0.2) | 0.0 (0.1) | 0.2 (0.3) | 0.3 (1.0) | – |
| 2nd year | 0.3 (0.3) | 0.1 (0.1) | 0.1 (0.2) | – | – | – |
| 3rd year | 0.2 (0.3) | 0.1 (0.1) | 0.1 (0.1) | – | – | – |
aAL was not included in the standard ophthalmological examination 1 year prior to start of therapy and was not included in the children who stopped atropine treatment.
bAllergies developed after 1 year. First-year data are on treatment, 2nd and 3rd year were without treatment.
cAdverse events included photophobia, reading difficulties, nightmares, and deterioration of behavioral problems in a child with diagnosis of ADHD.